{"component": "clause", "props": {"groups": [{"snippet_links": [{"key": "nothing-in-this-agreement", "type": "clause", "offset": [0, 25]}, {"key": "ownership-of", "type": "clause", "offset": [57, 69]}, {"key": "ip-rights", "type": "definition", "offset": [99, 108]}, {"key": "patent-rights", "type": "definition", "offset": [110, 123]}, {"key": "other-intellectual-property", "type": "definition", "offset": [127, 154]}, {"key": "a-party", "type": "clause", "offset": [172, 179]}, {"key": "date-from", "type": "definition", "offset": [209, 218]}, {"key": "one-party", "type": "definition", "offset": [219, 228]}, {"key": "other-party", "type": "definition", "offset": [236, 247]}, {"key": "license-to", "type": "clause", "offset": [253, 263]}, {"key": "the-foregoing", "type": "definition", "offset": [271, 284]}, {"key": "technology-transfer-and-license-agreement", "type": "clause", "offset": [310, 351]}], "snippet": "Nothing in this Agreement shall be construed to transfer ownership of or grant a license under any IP Rights, Patent Rights or other intellectual property or technology of a Party existing as of the Effective Date from one Party to the other Party. Any license to any of the foregoing shall be governed by the Technology Transfer and License Agreement.", "samples": [{"hash": "5lpgWJcqgDV", "uri": "/contracts/5lpgWJcqgDV#existing-ip", "label": "Joint Development Program and Cost Sharing Agreement (Micron Technology Inc)", "score": 21.8158795346, "published": true}, {"hash": "gVr3l0oADii", "uri": "/contracts/gVr3l0oADii#existing-ip", "label": "Joint Development Program Agreement (Micron Technology Inc)", "score": 21.0, "published": true}], "size": 3, "hash": "23f7391f19d89304bf5b10ed8077e95a", "id": 1}, {"snippet_links": [{"key": "including-without-limitation", "type": "clause", "offset": [34, 62]}, {"key": "other-intellectual-property-rights", "type": "definition", "offset": [86, 120]}, {"key": "on-the-effective-date", "type": "clause", "offset": [130, 151]}, {"key": "owned-and-controlled", "type": "definition", "offset": [161, 181]}, {"key": "in-this-agreement", "type": "clause", "offset": [203, 220]}, {"key": "each-party-will", "type": "clause", "offset": [291, 306]}, {"key": "title-and-interest", "type": "clause", "offset": [325, 343]}, {"key": "existing-intellectual-property-rights", "type": "clause", "offset": [359, 396]}], "snippet": "Any intellectual property rights, including without limitation, Patents, know-how and other intellectual property rights existing on the Effective Date shall be owned and controlled (except as set forth in this Agreement) by the respective Party only. Except as set forth in this Agreement, each Party will retain all right, title and interest in and to such existing intellectual property rights.", "samples": [{"hash": "jrFG0muajK8", "uri": "/contracts/jrFG0muajK8#existing-ip", "label": "License and Collaboration Agreement (Signal Genetics, Inc.)", "score": 27.9185489391, "published": true}], "size": 1, "hash": "bdc4bb0ee947177981e7241a81d23b2f", "id": 8}, {"snippet_links": [{"key": "each-party", "type": "clause", "offset": [0, 10]}, {"key": "sole-owner", "type": "definition", "offset": [28, 38]}, {"key": "no-right", "type": "clause", "offset": [74, 82]}, {"key": "other-party", "type": "definition", "offset": [115, 126]}, {"key": "in-accordance-with", "type": "definition", "offset": [135, 153]}, {"key": "the-licenses", "type": "clause", "offset": [154, 166]}], "snippet": "Each Party shall remain the sole owner of its Existing IP, and shall have no right in or to the Existing IP of the other Party, except in accordance with the licenses set forth herein.", "samples": [{"hash": "8oZ2rg6kIQz", "uri": "/contracts/8oZ2rg6kIQz#existing-ip", "label": "Collaboration Agreement (Quark Pharmaceuticals Inc)", "score": 21.8952772074, "published": true}, {"hash": "gKrzEycCs2d", "uri": "/contracts/gKrzEycCs2d#existing-ip", "label": "Collaboration Agreement (Quark Biotech Inc)", "score": 21.0, "published": true}], "size": 2, "hash": "d67f4f14e3053d15dcd99ce061494d9e", "id": 3}, {"snippet_links": [{"key": "each-party", "type": "clause", "offset": [0, 10]}, {"key": "title-and-interest", "type": "clause", "offset": [30, 48]}, {"key": "provider-agrees-to", "type": "clause", "offset": [89, 107]}, {"key": "contained-in", "type": "definition", "offset": [133, 145]}, {"key": "in-writing", "type": "clause", "offset": [184, 194]}, {"key": "in-advance", "type": "clause", "offset": [199, 209]}, {"key": "for-purposes-of-this", "type": "clause", "offset": [223, 243]}, {"key": "the-term", "type": "clause", "offset": [248, 256]}, {"key": "intellectual-property-rights", "type": "definition", "offset": [291, 319]}, {"key": "confidential-information-and", "type": "clause", "offset": [408, 436]}, {"key": "other-materials", "type": "clause", "offset": [441, 456]}, {"key": "owned-or-controlled", "type": "definition", "offset": [485, 504]}, {"key": "by-either-party", "type": "clause", "offset": [505, 520]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [521, 545]}, {"key": "scope-of-this", "type": "clause", "offset": [592, 605]}], "snippet": "Each party retains all right, title and interest in and to their respective Existing IP. Provider agrees to identify any Existing IP contained in a Deliverable in this PO or otherwise in writing and in advance to Mobileum. For purposes of this PO, the term \"Existing IP\" means all worldwide intellectual property rights in any and all technology, know how, software, data, ideas, formula, processes, charts, Confidential Information and any other materials or information that are (a) owned or controlled by either party as of the Effective Date, or (b) developed by either party outside the scope of this PO.", "samples": [{"hash": "1ECAjVN9Txr", "uri": "/contracts/1ECAjVN9Txr#existing-ip", "label": "Purchase Order", "score": 31.6110920647, "published": true}], "size": 1, "hash": "a8bba4f793c4eed69a0dfa2ab072efda", "id": 7}, {"snippet_links": [{"key": "nothing-in-this-agreement", "type": "clause", "offset": [0, 25]}, {"key": "ownership-of-the", "type": "clause", "offset": [47, 63]}, {"key": "spark-ip", "type": "definition", "offset": [64, 72]}, {"key": "novartis-ip", "type": "definition", "offset": [134, 145]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [155, 179]}, {"key": "each-case", "type": "definition", "offset": [190, 199]}, {"key": "owned-by", "type": "definition", "offset": [213, 221]}, {"key": "the-party", "type": "clause", "offset": [222, 231]}, {"key": "such-rights", "type": "definition", "offset": [239, 250]}], "snippet": "Nothing in this Agreement shall affect Spark\u2019s ownership of the Spark IP existing as the Effective Date or Novartis\u2019 ownership of the Novartis IP existing as of the Effective Date, which in each case shall remain owned by the Party having such rights.", "samples": [{"hash": "h7waLoGZ3Dr", "uri": "/contracts/h7waLoGZ3Dr#existing-ip", "label": "Licensing Agreement (Spark Therapeutics, Inc.)", "score": 29.1560574949, "published": true}], "size": 1, "hash": "42ef92b4dcf5ef84368df85b059ad0f8", "id": 5}, {"snippet_links": [{"key": "nothing-in-this-agreement", "type": "clause", "offset": [0, 25]}, {"key": "ownership-of-the", "type": "clause", "offset": [47, 63]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [82, 106]}, {"key": "each-case", "type": "definition", "offset": [180, 189]}, {"key": "owned-by", "type": "definition", "offset": [203, 211]}, {"key": "the-party", "type": "clause", "offset": [212, 221]}, {"key": "such-rights", "type": "definition", "offset": [229, 240]}], "snippet": "Nothing in this Agreement shall affect Akcea\u2019s ownership of the Akcea IP existing as of the Effective Date or PTC\u2019s ownership of PTC IP existing as of the Effective Date, which in each case shall remain owned by the Party having such rights.", "samples": [{"hash": "1xhjqHOh0ar", "uri": "/contracts/1xhjqHOh0ar#existing-ip", "label": "Collaboration and License Agreement (Akcea Therapeutics, Inc.)", "score": 29.8459958932, "published": true}, {"hash": "iGxTcfJ3vqN", "uri": "/contracts/iGxTcfJ3vqN#existing-ip", "label": "Collaboration and License Agreement (PTC Therapeutics, Inc.)", "score": 29.8432580424, "published": true}], "size": 3, "hash": "fc1aca81711c1bd8ce1aca1e6a705a8a", "id": 2}, {"snippet_links": [{"key": "each-party", "type": "clause", "offset": [0, 10]}, {"key": "sole-owner", "type": "definition", "offset": [28, 38]}, {"key": "sole-and-exclusive", "type": "clause", "offset": [52, 70]}, {"key": "title-to", "type": "clause", "offset": [71, 79]}, {"key": "all-intellectual-property-rights", "type": "clause", "offset": [89, 121]}, {"key": "owned-by", "type": "definition", "offset": [122, 130]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [134, 158]}], "snippet": "Each Party shall remain the sole owner of, and have sole and exclusive title to, any and all intellectual property rights owned by it as of the Effective Date.", "samples": [{"hash": "34fCcNW3yVa", "uri": "/contracts/34fCcNW3yVa#existing-ip", "label": "Exclusive License and Development Agreement (Sagimet Biosciences Inc.)", "score": 34.4729637235, "published": true}, {"hash": "jQoNbPpbljZ", "uri": "/contracts/jQoNbPpbljZ#existing-ip", "label": "Exclusive License and Development Agreement (Sagimet Biosciences Inc.)", "score": 32.2881587953, "published": true}], "size": 2, "hash": "add02d078580e19a593cb5efdd949145", "id": 4}, {"snippet_links": [{"key": "control-of", "type": "definition", "offset": [34, 44]}, {"key": "core-intellectual-property", "type": "definition", "offset": [65, 91]}], "snippet": "Core shall maintain ownership and control of all of its Existing Core Intellectual Property.", "samples": [{"hash": "dSsQdtVKtXO", "uri": "/contracts/dSsQdtVKtXO#existing-ip", "label": "Product Agreement (King Pharmaceuticals Inc)", "score": 21.0, "published": true}], "size": 1, "hash": "92eadf92ac8b1f0468041db921bbb2bd", "id": 6}, {"snippet_links": [{"key": "control-of", "type": "definition", "offset": [34, 44]}, {"key": "king-intellectual-property", "type": "definition", "offset": [58, 84]}], "snippet": "King shall maintain ownership and control of all Existing King Intellectual Property.", "samples": [{"hash": "dSsQdtVKtXO", "uri": "/contracts/dSsQdtVKtXO#existing-ip", "label": "Product Agreement (King Pharmaceuticals Inc)", "score": 21.0, "published": true}], "size": 1, "hash": "66c35656a31b5dc40ea26fd462d18c58", "id": 9}, {"snippet_links": [{"key": "title-and-interest", "type": "clause", "offset": [37, 55]}, {"key": "existing-intellectual-property", "type": "clause", "offset": [95, 125]}, {"key": "on-the-effective-date", "type": "clause", "offset": [162, 183]}, {"key": "subject-only", "type": "definition", "offset": [185, 197]}, {"key": "granted-to", "type": "definition", "offset": [231, 241]}, {"key": "this-agreement", "type": "clause", "offset": [253, 267]}, {"key": "the-applicable", "type": "clause", "offset": [274, 288]}, {"key": "transfer-date", "type": "definition", "offset": [405, 418]}, {"key": "right-to", "type": "definition", "offset": [432, 440]}], "snippet": "OGX shall have and retain all right, title and interest in or Control over, as applicable, all existing Intellectual Property owned or otherwise Controlled by it on the Effective Date, subject only to the licenses and other rights granted to Teva under this Agreement as to the applicable OGX Intellectual Property; provided, however, that upon [***] and [***], if any, required under this Agreement (\u201cIP Transfer Date\u201d), [***] the right to require [***] to [***], and [***] shall thereupon [***], its [***]; and", "samples": [{"hash": "jY69A29oH5L", "uri": "/contracts/jY69A29oH5L#existing-ip", "label": "Collaboration and License Agreement (Oncogenex Pharmaceuticals, Inc.)", "score": 21.180698152, "published": true}], "size": 1, "hash": "8795e45d8bb187fb2c3c139593fff5ad", "id": 10}], "next_curs": "ClQSTmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjALEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IhRleGlzdGluZy1pcCMwMDAwMDAwYQyiAQJlbhgAIAA=", "clause": {"title": "Existing IP", "size": 24, "children": [["enforcement-right", "Enforcement Right"], ["notification", "Notification"]], "parents": [["intellectual-property", "Intellectual Property"], ["ownership", "Ownership"], ["ownership-of-intellectual-property", "Ownership of Intellectual Property"], ["ownership-of-inventions-disclosure", "Ownership of Inventions Disclosure"], ["intellectual-property-ownership-protection-and-related-matters", "Intellectual Property Ownership Protection and Related Matters"]], "id": "existing-ip", "related": [["existing-intellectual-property", "Existing Intellectual Property", "Existing Intellectual Property"], ["intellectual-property-rights-invention-and-patent-rights", "INTELLECTUAL PROPERTY RIGHTS - INVENTION AND PATENT RIGHTS", "INTELLECTUAL PROPERTY RIGHTS - INVENTION AND PATENT RIGHTS"], ["intellectual-property-inventions-and-patents", "Intellectual Property, Inventions and Patents", "Intellectual Property, Inventions and Patents"], ["intellectual-property", "Intellectual Property", "Intellectual Property"], ["new-intellectual-property", "New Intellectual Property", "New Intellectual Property"]], "related_snippets": [], "updated": "2025-07-07T12:37:48+00:00", "also_ask": ["What are the essential elements to clearly define 'Existing IP' and avoid future disputes?", "How can the clause be negotiated to maximize protection for pre-existing rights while enabling project collaboration?", "What are the most common risks or ambiguities in 'Existing IP' clauses that lead to litigation?", "How do courts typically interpret 'Existing IP' provisions in the context of joint development agreements?", "How does this clause compare to industry standards or statutory definitions of pre-existing intellectual property?"], "drafting_tip": "Define 'Existing IP' precisely to avoid ambiguity; specify ownership and permitted uses to prevent future disputes; require disclosure of all relevant IP to ensure transparency.", "explanation": "The Existing IP clause defines and distinguishes intellectual property that each party owns prior to entering into the agreement. It typically requires the parties to identify and list their pre-existing patents, copyrights, trademarks, or other proprietary materials, ensuring these assets are not inadvertently transferred or affected by the new contract. This clause is essential for protecting each party\u2019s original intellectual property rights and preventing disputes over ownership of assets that were not developed as part of the collaboration."}, "json": true, "cursor": ""}}